Table 3.

Treatment effect on the health-related quality of life assessed with Short-Form 36

SF-36 score	Group		P value
	Group A (n = 20)	Group B (n = 20)
Physical functioning
Baseline	42.01 ± 13.47	32.83 ± 17.06	0.211
End of treatment	37.28 ± 12.76	38.42 ± 7.83	0.753
Role -physical
Baseline	31.51 ± 14.9	29.45 ± 15.51	0.670
End of treatment	37.88 ± 10.16	39.02 ± 12.49	0.768
Role-emotional
Baseline	32.01 ± 12.12	38.39 ± 12.68	0.112
End of treatment	36.99 ± 12.62	30.14 ± 16.95	0.182
Social functioning
Baseline	37.95 ± 14.06	33.82 ± 13.90	0.356
End of treatment	36.41 ± 13.03	30.07 ± 12.83	0.151
Body pain
Baseline	34.94 ± 14.39	30.13 ± 12.09	0.260
End of treatment	52.37 ± 17.00	41.32 ± 12.34	0.031
General health perceptions
Baseline	38.63 ± 11.66	31.82 ± 12.94	0.088
End of treatment	47.95 ± 18.58	31.84 ± 16.84	0.010
Mental health
Baseline	38.82 ± 14.72	39.20 ± 10.67	0.927
End of treatment	44.69 ± 10.79	38.88 ± 10.50	0.111
Energy/vitality
Baseline	38.08 ± 12.50	34.39 ± 12.64	0.360
End of treatment	42.95 ± 15.32	35.14 ± 10.87	0.084

All results are expressed as mean ± SD. Group A received amitriptyline and rabeprazole and group B received double dose of rabeprazole. P values are for the comparison of amitriptyline and rabeprazole vs double dose of rabeprazole at baseline and end of the treatment. Patients who received amitriptyline and rabeprazole treatment had a significantly greater improvement in the domains of body pain and general health perception than those who received a double dose of rabeprazole treatment (P = 0.031 and P = 0.01, respectively). The majority of the other domains of the Short-Form 36 (SF-36) did not reach statistical significance.